📊 Full opportunity report: A Data-Driven Index Of GLP-1 Stock And Cash-Pay Prices on IdeaNavigator AI — validation score, market gap, and execution plan.
Get privacy and security gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
TL;DR
An IdeaNavigator AI proposal calls for a pharmacy index that would track cash prices and dose-level availability for four branded GLP-1 drugs by ZIP code. The concept is a proposed business, not a launched service; its suggested validation targets are 200 consumer stock reports in one metro and paid interest from at least two business buyers within 60 days.
IdeaNavigator AI has proposed a pharmacy index that would help patients find branded GLP-1 drugs by dose, ZIP code, availability and cash price, while selling a normalized data feed to health care and benefits buyers. The proposal addresses a fragmented market, but the index has not been described as a launched or validated service.
The proposed consumer tool would cover Ozempic, Wegovy, Zepbound and Mounjaro. According to IdeaNavigator AI’s proposal, it would combine crowdsourced reports about local stock with publicly available prices from manufacturer-direct programs, retail pharmacies and price-comparison services. Patients could use it to look for a specific dose and compare cash prices in their area, with alerts for dose availability as a possible feature.
IdeaNavigator AI proposes pairing free consumer access with paid data products for telehealth prescribers, employer benefits teams, pharmacy benefit managers and brokers. The proposal says those buyers could license an availability and price feed or use a dashboard. It also mentions possible referral fees from legitimate pharmacy or manufacturer-direct channels and says revenue would not come from a clinical affiliate of the drugs themselves.
To test demand, the proposal calls for building a tracker in one metropolitan area and running separate landing-page tests for consumers and business buyers. Its suggested thresholds within 60 days are at least 200 submitted stock reports in that metro and paid pilots or letters of intent from at least two business prospects. These are targets stated in the proposal, not reported results.
Why Dose-Level Price Data Matters
IdeaNavigator AI says a usable index could help patients see how much cash prices vary for a particular drug and dose across nearby channels. Its proposal describes monthly prices ranging from about $199 to more than $1,000. It provides no date, drug-by-drug breakdown or common comparison method for that range, so it should not be read as a current quote for an individual patient.
For employers and other buyers, the proposed feed would offer a way to examine prices and local supply in a market where IdeaNavigator AI says GLP-1 medicines account for roughly 20% of pharmacy spending for employers. The proposal gives no survey, timeframe or spending definition for that figure. If validated, dose-level data could help buyers understand where prices differ and whether a product is available, though the proposal does not establish that the index would lower costs or resolve supply gaps.
The proposal frames the access problem as one that can persist even when national shortage status changes: patients may still encounter local gaps for a particular dose. A neutral, regularly updated comparison could be useful only if its listings are reliable, timely and clear about what a quoted price includes.
From Shortages to Fragmented Channels
IdeaNavigator AI’s proposal places the idea after FDA shortage-list decisions for two widely used GLP-1 ingredients. It says tirzepatide shortages were declared resolved in December 2024 and semaglutide shortages in February 2025. Those national determinations do not establish that every pharmacy has every dose in stock at a given time. The proposal describes continuing localized stockouts but provides no independent count or location-by-location data.
The proposal also points to a changing mix of purchasing routes. It names manufacturer-direct programs such as LillyDirect and NovoCare, cash-pay options involving Costco and Walmart, and pharmacy price-comparison services as channels that present information separately. It says the TrumpRx portal launched in February 2026, adding to that mix. These details are reported in the proposal; it argues that the offerings have not been brought together in a neutral, machine-readable index of dose-level supply and price.
As described by IdeaNavigator AI, the product would act as a comparison layer over existing channels, rather than as a pharmacy or drug manufacturer. Its usefulness would depend on how it collects and verifies reports, how often prices are refreshed, and whether patients can obtain prices shown under the stated conditions.
Questions Before a Reliable Index
IdeaNavigator AI’s proposal identifies no operating product, pilot results or signed buyers. It does not name pharmacies that have agreed to share live inventory, explain how crowdsourced reports would be verified, or specify how stale listings would be removed. Availability can change quickly, so those details would shape whether patients and institutional buyers could rely on the index.
The proposal also does not define the price-comparison rules. Cash prices may depend on the pharmacy, manufacturer program, eligibility requirements, location and other terms. It is unclear how the index would distinguish a generally available price from a limited offer, or whether it would show fees and other conditions alongside the headline amount.
The market figures cited in the proposal—including the approximate monthly price range and employer pharmacy-spending share—come without supporting methodology. The suggested pilot targets are goals, not evidence of demand. The proposal provides no information about operating costs, data access agreements, privacy practices for ZIP-code searches or the number of business buyers willing to pay.
A Metro Pilot Would Test Demand
IdeaNavigator AI’s proposed next step is a single-metro test over 60 days, covering four branded GLP-1 drugs and gathering consumer reports alongside normalized public price data. The proposal also calls for testing a consumer search page and a separate business pitch for an availability and price API with telehealth and employer-benefits prospects.
The proposal would treat 200 local stock reports and two paid pilots or letters of intent as evidence to assess the concept. The material provided identifies no pilot launch date, metro area or partner. Until those details and results are available, the index remains a business proposal rather than a source patients can use to confirm prices or stock.
Source: IdeaNavigator AI proposal for a GLP-1 pharmacy index
Key Questions
Has the GLP-1 pharmacy index launched?
No launch is reported. IdeaNavigator AI describes a proposed product and a plan to test it in one metro area.
Which drugs would it track?
The proposed index would cover Ozempic, Wegovy, Zepbound and Mounjaro, with searches by drug, dose and ZIP code.
What prices would the index compare?
According to IdeaNavigator AI’s proposal, it would compare cash-pay prices from manufacturer-direct programs, retail pharmacy channels and price-comparison services. The proposal does not give a complete pricing methodology or say how often listings would be updated.
How would the proposal be tested?
IdeaNavigator AI sets suggested 60-day targets of at least 200 consumer stock reports in one metro and at least two business prospects signing a paid pilot or letter of intent. The proposal does not report that these targets have been achieved.
Source: IdeaNavigator AI
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
